Subscribe
shutterstock_1843221310_maxshot_pl
MAXSHOT.PL / Shutterstock.com
1 June 2022Big Pharma

GSK bets $2.1bn on Boston-based biopharma company

GlaxoSmithKline has agreed to acquire Affinivax, a clinical-stage biopharmaceutical company based in Cambridge, Boston and focusing on developing vaccines.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Foley Hoag adds partner in Boston
22 August 2023   Biologics patent attorney aims to strengthen the firm’s global patent networks.
Big Pharma
GSK signs licence deals with three generics firms to make HIV preventative for low income countries
30 March 2023   The three companies will make low-cost versions of HIV PrEP drug | Generics will be available to consumers in 90 low- and middle-income countries.
Big Pharma
GSK presses court to deny Teva’s ‘skinny label’ petition
25 August 2022   Teva’s petition relies on a “blatantly misleading” question, argues GSK | Case presents “no new issues” that haven’t already been decided.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Big Pharma
Foley Hoag adds partner in Boston
22 August 2023   Biologics patent attorney aims to strengthen the firm’s global patent networks.
Big Pharma
GSK signs licence deals with three generics firms to make HIV preventative for low income countries
30 March 2023   The three companies will make low-cost versions of HIV PrEP drug | Generics will be available to consumers in 90 low- and middle-income countries.
Big Pharma
GSK presses court to deny Teva’s ‘skinny label’ petition
25 August 2022   Teva’s petition relies on a “blatantly misleading” question, argues GSK | Case presents “no new issues” that haven’t already been decided.

More on this story

Big Pharma
Foley Hoag adds partner in Boston
22 August 2023   Biologics patent attorney aims to strengthen the firm’s global patent networks.
Big Pharma
GSK signs licence deals with three generics firms to make HIV preventative for low income countries
30 March 2023   The three companies will make low-cost versions of HIV PrEP drug | Generics will be available to consumers in 90 low- and middle-income countries.
Big Pharma
GSK presses court to deny Teva’s ‘skinny label’ petition
25 August 2022   Teva’s petition relies on a “blatantly misleading” question, argues GSK | Case presents “no new issues” that haven’t already been decided.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB